Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot, CSF
Ordering Recommendation
Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy for CSF specimens only.
Mnemonic
Methodology
Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
Performed
Sun, Wed, Fri
Reported
1-6 days
New York DOH Approval Status
Specimen Required
CSF
Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min: 0.75 mL)
Refrigerated
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF | None Detected |
Interpretive Data
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
PCCA/ANNA antibodies are screened by IFA. If the IFA screen is indeterminate then the Immunoblot will be added. If the IFA screen is positive at 1:1, then a specific titer (PCCA or ANNA) and Immunoblot will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86255; if reflexed add 84182 x4 and/or 86256
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2010842 | Paraneoplastic Abs (PCCA/ANNA) IgG, CSF | 14247-1 |